How does psilocybin work in the brain?

Psilocybin is converted in the body to psilocin, which binds primarily to serotonin 5-HT2A receptors throughout the brain, particularly in the cortex. This binding disrupts normal patterns of neural communication, reducing activity in the default mode network (associated with self-referential thinking) and increasing connectivity between brain regions that do not normally communicate. The result is a more 'entropic' brain state associated with altered perception, emotional shifts, and ego dissolution. Psilocin also acts at other serotonin receptor subtypes (5-HT1A, 5-HT2C) contributing to the full range of effects.

What serotonin receptors does psilocybin act on?

Psilocin (the active metabolite of psilocybin) acts as a partial agonist at multiple serotonin receptor subtypes. Its primary psychedelic effects are mediated through agonism at the 5-HT2A receptor, which is distributed widely across the cortex. It also binds with meaningful affinity to 5-HT2C receptors (which modulate mood and appetite) and 5-HT1A receptors (which have anxiolytic and mood-stabilising effects). The relative contribution of each receptor subtype to the overall psychedelic experience remains an area of active research.

How is psilocybin metabolized in the body?

After ingestion, psilocybin is rapidly dephosphorylated by alkaline phosphatases in the gut wall and liver to produce psilocin, the pharmacologically active compound. Psilocin is further metabolised primarily by monoamine oxidase (MAO) and glucuronyl transferase enzymes. Peak plasma concentrations of psilocin are typically reached within 60–90 minutes of oral ingestion. Psilocin has a plasma half-life of approximately 2–3 hours, which corresponds to the gradual decline of psychedelic effects. Most metabolites are excreted in urine within 24 hours, though detection windows in drug testing vary.

What does current clinical research say about psilocybin?

Clinical research on psilocybin has grown substantially since the 2000s. Phase 2 trials at institutions including Johns Hopkins, Imperial College London, and NYU have shown significant reductions in depression severity, including treatment-resistant depression, with effects often persisting weeks to months after one or two sessions. Studies also show promising results for end-of-life anxiety, alcohol use disorder, and smoking cessation. In 2023, the FDA granted psilocybin Breakthrough Therapy designation for major depressive disorder. Phase 3 trials are ongoing. Most research emphasises that therapeutic effects are closely linked to psychological support and integration, not the drug alone.

Psilocybin Science and Pharmacology FAQ

A research-grounded look at how psilocybin interacts with the brain, how the body processes it, what neuroimaging reveals, and why the experience unfolds the way it does.

⚠️ Educational purposes only. Not medical or legal advice. Always consult qualified professionals.

Chemical Structure and Mechanism of Action

Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is a naturally occurring indole alkaloid belonging to the tryptamine class of compounds. Structurally, it is closely related to the neurotransmitter serotonin (5-hydroxytryptamine, or 5-HT) and to DMT (N,N-dimethyltryptamine). The molecule was first isolated and identified in 1958 by Swiss chemist Albert Hofmann — the same researcher who synthesised LSD in 1938 — from specimens of Psilocybe mexicana sent by mycologist Roger Heim.

Psilocybin is itself pharmacologically inactive. It acts as a prodrug: after ingestion, intestinal alkaline phosphatases rapidly dephosphorylate it to psilocin (4-hydroxy-DMT), which is the biologically active compound. Psilocin crosses the blood-brain barrier efficiently and exerts its primary effects through partial agonism at 5-HT2A receptors in the cortex. These receptors are highly expressed in glutamatergic pyramidal neurons of layer V in prefrontal and association cortices — regions involved in self-referential thought, executive function, and default mode network activity. Activation of cortical 5-HT2A receptors causes a dramatic increase in glutamate release and disrupts normal patterns of neural firing and synchronisation.

Neuroimaging: What Happens in the Brain

The advent of functional neuroimaging — particularly fMRI and MEG (magnetoencephalography) — has allowed researchers to observe psilocybin's effects on brain connectivity in real time. Seminal work by Robin Carhart-Harris and colleagues at Imperial College London, published in the Proceedings of the National Academy of Sciences (2012) and later in Nature (2016), revealed several consistent findings. Under psilocybin, activity in the default mode network (DMN) — a set of regions including the medial prefrontal cortex, posterior cingulate cortex, and angular gyrus that are active during self-referential thought and mind-wandering — is markedly suppressed. This disruption correlates strongly with subjective reports of ego dissolution and altered sense of self.

At the same time, psilocybin dramatically increases global functional connectivity: brain regions that do not normally communicate directly begin to show correlated activity, a state sometimes described as "hyperdimensional" or "entropic" brain activity. The 2014 paper by Carhart-Harris and colleagues introduced the concept of "neural entropy" to describe this more disordered, flexible state, in contrast to the more constrained, hierarchical organisation of the ordinary waking brain. Subsequent work by Enzo Tagliazucchi and others using EEG confirmed that psilocybin increases signal complexity and diversity of brain states. These findings have informed the "REBUS" (Relaxed Beliefs Under Psychedelics) model proposed by Carhart-Harris and Karl Friston, which frames the psychedelic state as one in which top-down predictive processing is weakened, allowing bottom-up signals — including emotional memories and sensory experiences — to exert greater influence on consciousness.

Pharmacokinetics: Absorption, Distribution, and Duration

When taken orally, psilocybin is absorbed through the gastrointestinal tract, with peak plasma concentrations of its active metabolite psilocin typically reached 80 to 100 minutes after ingestion. The onset of subjective effects generally begins 20 to 40 minutes after oral dosing, with peak effects at 60 to 120 minutes and a gradual return to baseline over 4 to 6 hours. The total experience typically lasts 4 to 8 hours depending on dose, individual metabolism, and whether food was consumed. Sublingual administration (dissolving under the tongue) or lemon tekking (acidic pre-hydrolysis) may accelerate onset and reduce overall duration.

Psilocin is metabolised primarily in the liver via glucuronidation and monoamine oxidase (MAO) activity. Urine concentration peaks around 3 hours after ingestion. Standard 12-panel drug tests do not screen for psilocybin or psilocin, as these compounds are structurally distinct from the immunoassay targets used in most workplace panels. Specialised laboratory tests using gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS) can detect psilocin metabolites, but these are not routinely used. Elimination half-life of psilocin is approximately 3 hours, meaning the compound is substantially cleared within 12 to 24 hours.

Tolerance, Addiction Potential, and Drug Interactions

Psilocybin and psilocin are not considered addictive by neuropharmacological or behavioural criteria. They do not cause physical dependence, do not produce withdrawal syndromes, and are not reinforcing in animal self-administration models (unlike cocaine, opioids, or alcohol). However, they do produce rapid functional tolerance through receptor downregulation: repeat doses taken within two to three days produce diminished effects. This cross-tolerance extends to other classic psychedelics including LSD and mescaline, all of which act primarily at 5-HT2A receptors.

Drug interactions are an important safety consideration. Psilocin's activity at serotonin receptors means that combinations with serotonergic medications — particularly MAOIs — can produce serotonin syndrome, a potentially life-threatening condition characterised by hyperthermia, agitation, clonus, and autonomic instability. SSRIs, particularly at higher doses, blunt the psychedelic response by occupying or downregulating 5-HT2A receptors. Lithium carbonate has been associated with reports of seizures in combination with classic psychedelics and should be avoided. Cannabis, while commonly combined recreationally, can substantially amplify and prolong psychedelic effects and increase the risk of anxiety and psychosis-like reactions, particularly in those with underlying vulnerability.

Frequently Asked Questions

Is psilocybin a serotonin or a dopamine drug?

Psilocybin's primary active metabolite, psilocin, is a partial agonist at serotonin (5-HT) receptors — particularly 5-HT2A, 5-HT2C, and 5-HT1A subtypes. It has minimal affinity for dopamine receptors. This distinguishes classic psychedelics from stimulants (which primarily act on dopamine) and entactogens like MDMA (which releases both serotonin and dopamine). The 5-HT2A partial agonism in the cortex is the mechanism most consistently linked to the perceptual, cognitive, and therapeutic effects of psilocybin.

Why does psilocybin cause visual hallucinations?

5-HT2A receptors are highly expressed in the visual cortex, particularly in layers II/III and V. Activation of these receptors disrupts the normal hierarchy of visual processing, allowing internally generated patterns and signals to intrude on or dominate perception. The result ranges from subtle visual enhancement (colours appearing more vivid, surfaces appearing to breathe) to complex, meaningful hallucinations at higher doses. Geometric patterns are common at low to moderate doses and are thought to arise from excitation of visual cortical circuits that normally represent basic spatial features.

What is the default mode network and why does psilocybin suppress it?

The default mode network (DMN) is a set of interconnected brain regions — including the medial prefrontal cortex, posterior cingulate cortex, precuneus, and angular gyrus — that are most active during self-referential thought, planning, daydreaming, and rumination. It is sometimes called the "narrative self" network because it underlies the brain's tendency to construct a continuous story of personal identity. Psilocybin reduces activity and connectivity within the DMN, which many researchers link to the dissolution of the habitual sense of self, reduced depressive rumination, and the sense of unity with one's environment reported by participants.

How is psilocybin different from LSD pharmacologically?

Both psilocybin and LSD are partial agonists at 5-HT2A receptors and produce broadly similar phenomenological effects. Key pharmacological differences include duration (LSD: 8–12+ hours vs psilocybin: 4–8 hours), affinity for dopamine receptors (LSD has significant D2 binding; psilocybin does not), and potency (LSD is active at microgram doses; psilocybin at milligram doses). LSD also has a longer biological half-life and more complex receptor profile, which may contribute to its longer and sometimes more unpredictable course. Both show cross-tolerance with one another and with mescaline.

Does psilocybin promote neuroplasticity?

Preclinical evidence suggests yes. A 2021 study published in Neuropsychopharmacology by Castrén and colleagues found that psilocybin promoted dendritic spine growth in mouse prefrontal cortex, with structural changes persisting for at least one month after a single dose. Earlier work by Ly and colleagues (Cell Reports, 2018) showed that both psilocybin and DMT promote structural and functional neuroplasticity in vitro, increasing synaptogenesis and dendritic complexity. These findings suggest that the therapeutic window may extend beyond the acute pharmacological effect, and that neuroplasticity-mediated changes in cortical circuitry could underpin lasting therapeutic benefits.

Can the brain become tolerant to psilocybin after a single use?

Yes. Rapid tachyphylaxis (tolerance) develops after a single psychedelic experience due to 5-HT2A receptor downregulation and internalisation. If psilocybin is taken on consecutive days, each subsequent dose produces markedly diminished effects. Full receptor resensitisation typically takes two to three days after a single dose. This is why repeated-use addiction is pharmacologically uncharacteristic of classic psychedelics — the receptor mechanism that would normally drive compulsive redosing effectively prevents it.

Does psilocybin affect serotonin levels directly?

Psilocin does not cause significant serotonin release or reuptake inhibition in the way SSRIs or MDMA do. It acts primarily as a receptor agonist, mimicking the shape of serotonin at 5-HT2A and related receptor subtypes without substantially altering endogenous serotonin concentrations. This mechanism is important to understand because it means psilocybin's therapeutic effects are distinct from SSRIs and cannot simply be explained by "more serotonin." The therapeutic hypothesis centres on receptor activation patterns, network-level reorganisation, and neuroplasticity rather than neurotransmitter repletion.

What is the lethal dose of psilocybin?

In rodent studies, the estimated LD50 (lethal dose for 50% of subjects) for psilocybin is extremely high — approximately 280 mg/kg when administered intravenously. Scaling to human weight, a lethal dose would require consuming kilograms of dried mushrooms. No verified human fatality has been attributed solely to psilocybin toxicity. The rare deaths associated with magic mushroom use have involved accidents during intoxication, pre-existing cardiac conditions, or polydrug use. This physiological safety profile places psilocybin among the substances rated lowest in toxicity in comparative risk analyses such as the 2010 Nutt et al. paper in The Lancet.

How long is psilocybin detectable in urine?

Psilocin — the active metabolite of psilocybin — has an elimination half-life of roughly 3 hours and is substantially cleared from urine within 15 to 24 hours for most people. Standard urine drug tests (immunoassay panels) do not screen for psilocybin or psilocin. Specialised confirmatory tests using LC-MS or GC-MS can detect psilocin glucuronide in urine for up to 24–48 hours post-ingestion. Hair follicle tests could theoretically detect it for longer periods, though such testing for psilocybin is not employed in any known routine occupational or legal screening context.

What is the "entropic brain" theory?

The "entropic brain" theory, developed by Robin Carhart-Harris and published in Frontiers in Human Neuroscience in 2014, proposes that psychedelics temporarily increase the entropy — the disorder or unpredictability — of brain activity. Healthy waking consciousness occupies a middle range of neural entropy, between the overly rigid, low-entropy states associated with depression and OCD, and the excessively high-entropy states of psychosis and certain drug states. Classic psychedelics, by disrupting top-down hierarchical processing (particularly via DMN suppression and 5-HT2A activation), temporarily push the brain into a higher-entropy, more flexible state. The theory suggests this window of increased plasticity and openness may be what allows therapeutic re-patterning of entrenched cognitive habits.